Revaccination following CAR-T therapy: a needs assessment
Background: CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment for relapsed/refractory large B-cell lymphoma, offering promising remission rates. However, it carries significant infectious risks, necessitating revaccination for infection prevention.Methods: This...
Saved in:
| Main Authors: | Robert Clayden, Barbara Gunka, Brittany Salter, Audrey Y. H. Dong, Kylie Lepic, Gwynivere Davies, Amaris Balitsky |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2025.2519865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
by: Elvira Umyarova, et al.
Published: (2025-03-01) -
Can positron emission tomography with 18F-FDG substitute bone marrow biopsy for detecting bone marrow infiltration in patients with large B-cell lymphoma?
by: Susan Adil Ali, et al.
Published: (2025-07-01) -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01) -
Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01) -
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
by: Dito Anurogo, et al.
Published: (2024-07-01)